8-K: Caribou Biosciences Presents Promising Clinical Data for CB-010 CAR-T Therapy in Lymphoma

Caribou Biosciences announced updated clinical data from its ANTLER Phase 1 trial showing that CB-010, an allogeneic CAR-T cell therapy, demonstrates potential to rival autologous CAR-T therapies, particularly with partial HLA matching.

Summary

• Caribou Biosciences has released updated clinical data from the ANTLER Phase 1 trial for CB-010, an off-the-shelf CAR-T cell therapy targeting CD19 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
• The trial evaluated three dose levels of CB-010 in 46 patients, with 16 in dose escalation and 30 in dose expansion focusing on second-line large B-cell lymphoma (2L LBCL).
• A retrospective analysis showed that patients receiving CB-010 from donors with 4 matching HLA alleles (partial HLA matching) had a median progression-free survival (PFS) of 14.4 months, compared to 2.8 months for those with 3 HLA matches.
• In a subset of 11 LBCL patients with 4 HLA matches, the median PFS was not reached.
• The recommended Phase 2 dose (RP2D) for CB-010 was determined to be 80x10^6 CAR-T cells.
• The company plans to enroll approximately 20 additional 2L LBCL patients with partial HLA matching and expects initial data in the first half of 2025.
• A pivotal Phase 3 trial is planned for the second half of 2025, pending confirmation of improved outcomes in the partially HLA matched cohort.
• CB-010 was generally well-tolerated, with no Grade 3 or higher cytokine release syndrome (CRS) or graft-versus-host disease (GvHD) observed.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data for CB-010, particularly with partial HLA matching, and outlines a clear path forward with a planned Phase 3 trial. The safety profile is also encouraging. However, there are some risks and uncertainties associated with clinical trials, which temper the overall sentiment slightly.

Positives

• CB-010 demonstrates promising efficacy, particularly with partial HLA matching, showing a median PFS of 14.4 months.
• The therapy has a favorable safety profile with no Grade 3 or higher CRS or GvHD observed.
• CB-010 is an off-the-shelf therapy, potentially reducing treatment delays compared to autologous CAR-T therapies.
• The company is planning a pivotal Phase 3 trial in the second half of 2025, indicating confidence in the therapy's potential.
• The partial HLA matching strategy is straightforward to integrate into manufacturing, ensuring broad patient access.
• CB-010 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations by the FDA.

Negatives

• Five patient deaths occurred due to adverse events following CB-010 infusion, with one possibly related to the treatment.
• Some patients experienced prolonged cytopenias, though most recovered by day 35.
• There were some instances of infections and immune effector cell-associated neurotoxicity syndrome (ICANS), though generally manageable.

Risks

• The clinical trial data is still preliminary, and further studies are needed to confirm the efficacy and safety of CB-010.
• There is a risk that the results from the additional 20 patients may not confirm the improved outcomes seen with partial HLA matching.
• The pivotal Phase 3 trial is subject to regulatory approvals and may face delays.
• The company is reliant on third parties for manufacturing, which could pose a risk to supply.
• There are inherent risks in the development of cell therapy products, including potential safety issues and regulatory hurdles.

Future Outlook

Caribou plans to enroll approximately 20 additional 2L LBCL patients with partial HLA matching and expects initial data in the first half of 2025. A pivotal Phase 3 trial is planned for the second half of 2025, pending confirmation of improved outcomes in the partially HLA matched cohort. The company also plans to open the ANTLER study to patients who have relapsed following any prior CD19-targeted therapy.

Management Comments

• Rachel Haurwitz, PhD, Caribou's president and chief executive officer, stated that patients who receive partially HLA matched CB-010 have improved efficacy and durability outcomes that are on par with approved autologous CAR-T cell therapies.
• Tim Kelly, Caribou's chief technology officer, noted that integrating partial HLA matching into manufacturing for CB-010 is straightforward, enabling Caribou to deliver CB-010 as a readily available off-the-shelf CAR-T cell therapy.
• Boyu Hu, MD, an investigator on the ANTLER trial, stated that the partial HLA matching strategy is incredibly intriguing and further evaluation is supported by the ASCO data presentation.

Industry Context

This announcement is significant as it highlights the potential of allogeneic CAR-T cell therapy to overcome the limitations of autologous CAR-T therapies, such as manufacturing delays and patient-specific requirements. The partial HLA matching strategy could be a key differentiator for Caribou in the competitive landscape of cell therapies. The results are being presented at the 2024 ASCO Annual Meeting, a major event in the oncology field.

Comparison to Industry Standards

• The document compares CB-010's results to the ZUMA-7 trial for Yescarta, an autologous CAR-T therapy, noting that the median PFS of 14.4 months with partial HLA matching in the ANTLER trial is potentially on par with the results from ZUMA-7.
• The document also notes that the safety profile of CB-010, with no Grade 3 CRS or GvHD, compares favorably to the safety profile of Yescarta as reported in the ZUMA-7 trial and other studies.
• The document highlights that CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a unique feature designed to improve activity against diseases by limiting premature CAR-T cell exhaustion.
• The document also notes that CB-010 is the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the second-line LBCL setting.

Stakeholder Impact

• Shareholders: The positive clinical data and plans for a Phase 3 trial are likely to be viewed favorably by investors.
• Patients: The potential for an effective and readily available off-the-shelf CAR-T therapy is a significant benefit for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
• Employees: The progress of CB-010 is likely to boost morale and provide a sense of accomplishment.
• Healthcare providers: The availability of an off-the-shelf CAR-T therapy could simplify treatment logistics and improve patient access.

Next Steps

• Enroll approximately 20 additional 2L LBCL patients with partial HLA matching.
• Report initial data from the 2L LBCL and CD19 relapsed cohorts in the first half of 2025.
• Initiate a pivotal Phase 3 clinical trial in 2L LBCL patients in the second half of 2025.
• Open the ANTLER study to patients who have relapsed following any prior CD19-targeted therapy.

Key Dates

Keywords

CAR-T cell therapy, allogeneic, CB-010, lymphoma, HLA matching, CRISPR, cancer, B-NHL, PFS, clinical trial